HKSE:2315
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. · HKSE · Healthcare · HKD · FY for 2025
Figures on this page computed 2026-11-08 13:27 UTC
Last close
n/aHKD
Market data
82.2xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
- Computed from the filing for 2025
21.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
12.6%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
20.5%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.27Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- HKD
- computed
Price is the furthest below its sector's middle: 0.12 against 0.36 on the market's range.
- Growth40.3%94 of 100, above its sector
- Returns on capital21.5%74 of 100, above its sector
- Margins75.8%84 of 100, above its sector
- Price82.2x12 of 100, below its sector
- Safety0.2763 of 100, above its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
All from 100
lens 2 of 9Sales
544Shares in issue
101- Profit, where the first year is 100: n/aNot enough filed years carry this line for it to be drawn. No line is drawn flat in its place.
Sales is at 544, Shares in issue is at 101, against 100 in 2020.
Sales is at 544, Shares in issue is at 101, against 100 in 2020.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales, where the first year is 100544
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Profit, where the first year is 100n/a
Not held.
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY
Shares in issue, where the first year is 100101
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- CNY